Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PELI1 | Q96FA3 | 2/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28051267 | 0.82 | IMPDH2 (0.47) | IMPDH2ENPP3ENPP1ALDH1A1MEN1 | |
| SCHEMBL8055265 | 0.81 | ESR1 (0.39) | IMPDH2LPLLIPGCSNK2A1ENPP3 | |
| SCHEMBL14003430 | 0.79 | S1PR4 (0.39) | IMPDH2CSNK2A1PDE10AALDH1A1MEN1 | |
| SCHEMBL5795534 | 0.76 | ALDH1A1 (0.43) | IMPDH2CSNK2A1PDE10AALDH1A1MEN1 | |
| SCHEMBL20777196 | 0.76 | CSNK2A1 (0.41) | IMPDH2CSNK2A1PDE10ACYP3A4 | |
| SCHEMBL10304989 | 0.76 | ABL1 (0.41) | IMPDH2CSNK2A1PDE10AALDH1A1CYP1A2 | |
| SCHEMBL28513436 | 0.74 | CSNK2A1 (0.40) | IMPDH2CSNK2A1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL10035040 | 0.73 | PPARG (0.48) | ALDH1A1MEN1CYP1A2CYP3A4KMT2A | |
| SCHEMBL28925250 | 0.73 | ALDH1A1 (0.36) | IMPDH2LPLLIPGCSNK2A1ALDH1A1 | |
| SCHEMBL20036777 | 0.73 | TOP2A (0.38) | IMPDH2LPLLIPGCSNK2A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251396-B2 | Amide compound and use of same for noxious arthropod control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20170295789-A1 | AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-3178322-A1 | AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | Sumitomo Chemical Company Limited (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-6342497-B1 | 2″-deoxy hygromycin derivatives | PFIZER INC | 2002-01-29 | — | — | US | disclosed |
| US-6313100-B1 | ANTIBACTERIAL, ANTIPROTOZOA AGENTS | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1077984-A1 | 2\"-DEOXY HYGROMYCIN DERIVATIVES | Pfizer Products Inc. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| WO-1999057127-A1 | 2'-DEOXY HYGROMYCIN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170295789-A1 | AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | OPRM1, TRPA1, L3MBTL3 | IMPDH2 4570/4885LPL 3462/4885LIPG 3721/4885 |
| US-10251396-B2 | Amide compound and use of same for noxious arthropod control | OPRM1, TRPA1, L3MBTL3 | IMPDH2 4570/4885LPL 3462/4885LIPG 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.